Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification.
Lieve KV, van der Werf C, Kallas D, Denjoy I, Bos JM, Aiba T, Behr ER, van den Berg MP, Bergeman AT, Blom NA, Borggrefe M, Brugada R, Carrillo Mora LM, Chorin E, Crotti L, Davis A, Drago F, Dusi V, Extramiana F, Franciosi S, Giudicessi JR, González Llopis FÁ, Haugaa KH, van den Heuvel F, Horie M, Ingles J, Kammeraad J, Kannankeril PJ, Khan HR, Krahn AD, MacIntyre C, Maltret A, Marjamaa A, Ohno S, Peltenburg PJ, Perez GJ, Probst V, Roberts JD, Robyns T, Rootwelt-Norberg C, Roses I Noguer F, Roston TM, Rydberg A, Sacher F, Sarquella-Brugada G, Schwartz PJ, Semsarian C, Shimizu W, Starling L, Sumitomo N, Skinner JR, Tavacova T, Tfelt-Hansen J, Till JA, Yap SC, Wada Y, Wangüemert F, Zorio E, Ackerman MJ, Leenhardt A, Sanatani S, Tanck MW, Wilde AA.
Lieve KV, et al. Among authors: van den berg mp.
Eur Heart J. 2025 Dec 19:ehaf965. doi: 10.1093/eurheartj/ehaf965. Online ahead of print.
Eur Heart J. 2025.
PMID: 41416846